Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 81

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 81
---
fusion will also reimburse banks, brokerage firms, custodians, trustees, nominees and fiduciaries for their expenses incurred in sending proxies and proxy materials to
beneficial owners of Enfusion Common Stock.

Adjournments

The Special Meeting may be adjourned by the presiding officer or Enfusion Stockholders representing a majority of the voting power present at
the Special Meeting if no quorum is present, or by the presiding officer if (i) the Enfusion Board determines that adjournment is necessary or appropriate to enable Enfusion Stockholders to consider fully information which the Enfusion Board
determines has not been made sufficiently or timely available to stockholders, or (ii) if the Enfusion Board determines that adjournment is otherwise in the best interests of Enfusion. Additionally, the Special Meeting may be adjourned if
sufficient votes are cast in favor of the Adjournment Proposal whether or not there is a quorum.

Notice need not be given of any
adjourned meeting if the time and place, if any, thereof and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present and vote at such adjourned meeting are announced at the meeting at which the
adjournment is taken unless the adjournment is for more than 30 days, in which case a notice of the adjourned meeting will be given to each stockholder of record entitled to vote at the meeting. If, after any adjournment, a new record date for the
stockholders entitled to vote is fixed for any adjourned meeting, notice of the place, if any, date, and time of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be
present and vote at such adjourned meeting must be given to each stockholder of record entitled to vote at the meeting.

Questions and Additional Information

You may contact Enfusion’s proxy solicitor, Innisfree, 501 Madison Avenue, 20
Floor, New York City, NY 10022, with any questions about the Special Meeting, the Transactions, the proposals or this Proxy Statement/Prospectus, if you would like additional copies of the Proxy Statement/Prospectus, if you need to obtain proxy
cards or other information related to the proxy solicitation or if you need help submitting a proxy or voting your shares of Enfusion Common Stock or Enfusion Class B Common